RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 3

Registered title, quoted from ClinicalTrials.gov

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 27 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 27

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Cancer Hospital of Xinjiang Medical University新疆医科大学附属肿瘤医院UrumqiHospital page
  2. Study siteAffiliated Hospital of Guizhou Medical University贵州医科大学附属医院GuiyangHospital page
  3. Study siteAffiliated Hospital of Xuzhou Medical University徐州医科大学附属医院XuzhouHospital page
  4. Study siteAnhui Provincial Cancer Hospital安徽省肿瘤医院HefeiHospital page
  5. Study siteChongqing University Cancer Hospital重庆大学附属肿瘤医院ChongqingHospital page
  6. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  7. Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
  8. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  9. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  10. Study siteHainan General Hospital / Hainan Medical University hospitals海南医学院附属医院/海南省人民医院HaikouHospital page
  11. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  12. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  13. Study siteInstitute of Hematology & Blood Diseases Hospital, CAMS & PUMC中国医学科学院血液病医院(血液学研究所)TianjinHospital page
  14. Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
  15. Study siteJiangxi Cancer Hospital江西省肿瘤医院NanchangHospital page
  16. Study siteNanfang Hospital南方医科大学南方医院GuangzhouHospital page
  17. Study sitePeking University First Hospital北京大学第一医院BeijingHospital page
  18. Study sitePeking University Third Hospital北京大学第三医院BeijingHospital page
  19. Study siteSecond Xiangya Hospital中南大学湘雅二医院ChangshaHospital page
  20. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  21. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  22. Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
  23. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  24. Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
  25. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  26. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  27. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06136559, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV deoxyribonucleic acid (DNA) viral load before randomization.

    Inclusion criterion 5

    Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.

    Exclusion criterion 11

  3. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before randomization.

    Inclusion criterion 3

  4. Has an active hepatitis B virus/ hepatitis C virus (HBV/HCV) infection.

    Exclusion criterion 1

    Has known additional malignancy that is progressing or has required active treatment within the past 2 years.

    Exclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06136559, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Confirmed diagnosis of CLL/SLL and active disease clearly documented to have a need to initiate therapy.
  • Has at least 1 marker of disease burden.
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before randomization.
  • Has the ability to swallow and retain oral medication.
  • Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV deoxyribonucleic acid (DNA) viral load before randomization.
  • Participants with history of hepatitis C virus (HCV) infection are eligible if HCV ribonucleic acid (RNA) viral load is undetectable at screening.
  • Participants with human immunodeficiency virus (HIV) who meet ALL eligibility criteria.

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has an active hepatitis B virus/ hepatitis C virus (HBV/HCV) infection.
  • Has gastrointestinal (GI) dysfunction that may affect drug absorption.
  • Has diagnosis of Richter Transformation or active central nervous system (CNS) involvement by CLL/SLL.
  • Has had acquired immune deficiency syndrome (AIDS)-defining opportunistic infection in the past 12 months before screening.
  • Has clinically significant cardiovascular disease.
  • Has hypersensitivity to nemtabrutinib or contraindication to ibrutinib or acalabrutinib, or any of the excipients.
  • Has history of severe bleeding disorder.
  • Has known additional malignancy that is progressing or has required active treatment within the past 2 years.
  • Has received any systemic anticancer therapy for CLL/SLL.
  • Is currently being treated with p-glycoprotein (P-gp) substrates with a narrow therapeutic index, cytochrome P450 3A (CYP3A) strong or moderate inducers or CYP3A strong inhibitors.
  • Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.
  • Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
  • Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration.
  • Has active infection requiring systemic therapy, including intravenous (IV) antibiotics during screening.
  • Participants who have not adequately recovered from major surgery or have ongoing surgical complications.

Quoted from ClinicalTrials.gov, NCT06136559, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06136559, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06136559